Pulse Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 23-10-2024
- Paid Up Capital ₹ 7.95 M
as on 23-10-2024
- Company Age 29 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 371.63 Cr
as on 23-10-2024
- Revenue 69.36%
(FY 2023)
- Profit 187.47%
(FY 2023)
- Ebitda 190.86%
(FY 2023)
- Net Worth 0.53%
(FY 2023)
- Total Assets 2.54%
(FY 2023)
About Pulse Pharma
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 7.95 M.
The company has closed loans amounting to ₹371.63 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Jyoti Bahri and Deepak Bahri serve as directors at the Company.
- CIN/LLPIN
U74899DL1995PTC064858
- Company No.
064858
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 Jan 1995
- Date of AGM
12 Aug 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Pulse Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jyoti Bahri  | Director | 31-Jan-1995 | Current |
| Deepak Bahri | Director | 31-Jan-1995 | Current |
Financial Performance and Corporate Structure Insights of Pulse Pharma.
Pulse Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 69.36% increase. The company also saw a substantial improvement in profitability, with a 187.47% increase in profit. The company's net worth moved up by a moderate rise of 0.53%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pulse Pharma?
In 2023, Pulse Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Rubicon Securities Private LimitedActive 32 years 10 monthsJyoti Bahri and Deepak Bahri are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Citibank N.A Creation Date: 05 Jun 2012 | ₹7.00 Cr | Satisfied |
Canara Bank Creation Date: 23 Aug 2008 | ₹130.99 Cr | Satisfied |
Icici Bank Limited Creation Date: 16 May 2006 | ₹28.34 Cr | Satisfied |
How Many Employees Work at Pulse Pharma?
Pulse Pharma has a workforce of 3 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pulse Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pulse Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
